Hydrocortisone/Pramoxine Shortage: What Providers and Prescribers Need to Know in 2026

Hydrocortisone/Pramoxine is a widely prescribed topical combination product with a generally favorable availability profile — but formulation-specific supply inconsistencies, particularly with aerosol foam preparations, continue to create patient access challenges in 2026. This guide is designed to help prescribers navigate the current landscape with practical substitution strategies and patient communication tools.

Current Availability by Formulation

Providers should understand that availability varies substantially across formulations:

Cream (1%/1%, 2.5%/1%): Broadly available from multiple generic manufacturers. Ferndale Laboratories, Saptalis Pharmaceuticals (TruPharma), Padagis, and others produce cream formulations. Most patients can fill these at major retail and independent pharmacies.

Lotion (1%/1%, 2.5%/1%): Available but less consistently stocked. Some pharmacies may need to special order. Generally procurable with 1-3 days lead time.

Ointment: Availability is inconsistent. Note that some 2.5%/1% ointment formulations are not FDA-approved or regulated as drug products — verify with your pharmacist before prescribing.

Aerosol foam (Proctofoam HC and generics): Structurally limited supply. The brand product (Schwarz Pharma/UCB) has been largely discontinued. Generic aerosol foam requires specialized pressurized manufacturing infrastructure; very few producers are active. Expect intermittent to chronic unavailability at retail pharmacies.

Why the Foam Shortage Persists

The aerosol foam availability issue is not a temporary manufacturing disruption — it is a structural market failure. The key drivers include:

Manufacturing complexity: aerosol foam requires pressurized canisters, propellants, and specialized fill lines not available to most generic manufacturers

Brand discontinuation: the originator has largely exited production

Low market incentive: niche patient population generates insufficient revenue to attract new generic entrants

Fragile supply chain: with 2-3 active producers, any single-site disruption causes national impact

Clinical Substitution Strategies

When the foam formulation is unavailable, these evidence-informed substitutions are available:

Formulation Switch (First-Line)

For most patients, switching from Hydrocortisone/Pramoxine foam to the cream or lotion formulation is clinically appropriate. The active ingredients (hydrocortisone 1% + pramoxine HCl 1%) are identical. Patient preference for the foam delivery system (particularly for internal hemorrhoid application) is valid but should be weighed against the practical inability to access the product. In clinical practice, most patients achieve equivalent symptom control with the cream.

39,049+ patients found their medications in stock

39K+

Find Hydrocortisone/Pramoxine In Stock Today →

Therapeutic Class Alternatives

If the combination product is unavailable in any formulation, or if a different clinical approach is warranted:

Hydrocortisone 2.5% cream/ointment (Anusol-HC, generics): Anti-inflammatory without anesthetic. Appropriate for inflammation-dominant presentations.

Lidocaine/Hydrocortisone combinations (Ana-Lex, Lidamantle HC): Dual-action alternative using lidocaine rather than pramoxine. Pramoxine's unique chemical structure reduces cross-sensitivity risk with amide and ester anesthetics; lidocaine is an amide anesthetic, so consider allergy history when substituting.

Rectiv (nitroglycerin 0.4% ointment): For anal fissure specifically; promotes healing via internal anal sphincter relaxation. Not appropriate for hemorrhoids or inflammatory dermatoses.

Compounded formulations: A PCAB-accredited compounding pharmacy can prepare Hydrocortisone/Pramoxine in any formulation — including foam — using bulk pharmaceutical ingredients. This is a valid escalation option when commercial products are unavailable.

Prescribing Notes and FDA Status

Prescribers should be aware that some Hydrocortisone/Pramoxine formulations — particularly certain 2.5%/1% creams and ointments from specific manufacturers — are not FDA-approved or regulated as drug products. These are marketed under the FDA's enforcement discretion. Ensure your prescriptions are filled with products that carry appropriate regulatory status if this is a clinical concern.

Skip the calls, skip the stress.

Find Hydrocortisone/Pramoxine In Stock Today →

50K+

Medications
Found

99%

Success
Rate

6+

Hours saved
on average

Helping Patients Find Their Medication

Consider recommending [@portabletext/react] Unknown block type "span", specify a component for it in the `components.types` prop to your patients. medfinder calls pharmacies on the patient's behalf to find which ones have a specific medication, formulation, and strength in stock. This is particularly useful for patients prescribed foam formulations, who may spend significant time calling pharmacies only to be turned away repeatedly.

Cost Considerations for Patients

Patients without insurance coverage — or those on plans that exclude topical combination products — may face significant out-of-pocket costs. Brand-name Proctofoam HC can cost $200-$500+ for a 10g canister without insurance. Generic Hydrocortisone/Pramoxine cream with a GoodRx coupon runs as low as $43 for 30g. When prescribing, writing for the generic cream formulation may substantially reduce patient cost burden. The Analpram HC manufacturer savings card allows eligible commercially insured patients to pay as little as $20 per prescription.

Documentation and Prior Authorization

Some insurance plans require prior authorization for brand-name Hydrocortisone/Pramoxine products or specific formulations. When writing for the brand or for a less common form, anticipate the possibility of a PA request. For the PA, document: indication (hemorrhoids, anal fissure, specific dermatosis), formulation rationale (patient inability to self-apply cream vs. foam), and trial of lower-cost alternatives if applicable.

Summary for Prescribers

When prescribing Hydrocortisone/Pramoxine in 2026, default to the cream or lotion formulation for maximum patient access. Reserve foam prescriptions for patients with a strong clinical rationale, and proactively discuss formulation flexibility with patients. For providers who want to help their patients navigate pharmacy access more efficiently, see our guide: [@portabletext/react] Unknown block type "span", specify a component for it in the `components.types` prop.